Pre- and post-procedure risk prediction models for post-endoscopic retrograde cholangiopancreatography pancreatitis

被引:18
|
作者
Park, Chan Hyuk [1 ]
Park, Se Woo [2 ]
Yang, Min Jae [3 ]
Moon, Sung Hoon [4 ]
Park, Da Hae [2 ]
机构
[1] Hanyang Univ, Coll Med, Dept Internal Med, Guri Hosp, Guri, South Korea
[2] Hallym Univ, Dongtan Sacred Heart Hosp, Coll Med, Div Gastroenterol,Dept Internal Med, 7 Keunjaebong Gil, Hwaseong Si 18450, Gyeonggi Do, South Korea
[3] Ajou Univ, Dept Gastroenterol, Sch Med, Suwon, South Korea
[4] Hallym Univ, Coll Med, Div Gastroenterol, Dept Internal Med,Sacred Heart Hosp, Anyang, South Korea
来源
SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES | 2022年 / 36卷 / 03期
关键词
Endoscopic retrograde cholangiopancreatography; Pancreatitis; Risk; Prediction; Score; DOUBLE-GUIDEWIRE TECHNIQUE; ERCP PANCREATITIS; CANNULATION; COMPLICATIONS; PREVENTION; EFFICACY;
D O I
10.1007/s00464-021-08491-1
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background Post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP) is the most common serious adverse event. Given recent endoscopic advances, we aimed to develop and validate a risk prediction model for PEP using the latest clinical database. Methods We analyzed the data of patients with naive papilla who underwent endoscopic retrograde cholangiopancreatography (ERCP). Pre-ERCP and post-ERCP risk prediction models for PEP were developed using logistic regression analysis. Patients were classified into low- (0 points), intermediate- (1-2 points), and high-risk (>= 3 points) groups according to point scores. Results We included 760 and 735 patients in the derivation and validation cohorts, respectively. The incidence of PEP was 5.5% in the derivation cohort and 3.9% in the validation cohort. Age <= 65 (1 point), female sex (1 point), acute pancreatitis history (2 points), malignant biliary obstruction (2 points [pre-ERCP model] or 1 point [post-ERCP model]), and pancreatic sphincterotomy (2 points, post-ERCP model only) were independent risk factors. In the validation cohort, the high-risk group (>= 3 points) had a significantly higher risk of PEP compared to the low- or intermediate-risk groups under the post-ERCP risk prediction model (low: 2.0%; intermediate: 3.4%; high: 18.4%), while there was no significant between-group difference under the pre-ERCP risk prediction model (low: 2.2%; intermediate: 3.8%; high: 6.9%). Conclusions We developed and validated pre-ERCP and post-ERCP risk prediction models. In the latter, the high-risk group had a higher risk of PEP development than the low- or intermediate-risk groups. Our study findings will help clinicians stratify patient risk for the development of PEP.
引用
收藏
页码:2052 / 2061
页数:10
相关论文
共 50 条
  • [21] How to Prevent Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis
    Boskoski, Ivo
    Costamagna, Guido
    GASTROENTEROLOGY, 2020, 158 (08) : 2037 - 2040
  • [22] Prevention of Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis: Medications and Techniques
    Wang, Andrew Y.
    Strand, Daniel S.
    Shami, Vanessa M.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2016, 14 (11) : 1521 - +
  • [23] Statin consumption and risk of post-endoscopic retrograde cholangiopancreatography pancreatitis
    Martinez-Moneo, Emma
    Cardenas-Jaen, Karina
    Fernandez-Laso, Ana B.
    Millastre-Bocos, Judith
    Torralba-Gallego, Ainara
    Martin-Arriero, Silvia
    Alfaro-Almajano, Enrique
    Garcia-Rayado, Guillermo
    de-Madaria, Enrique
    PANCREATOLOGY, 2020, 20 (05) : 801 - 805
  • [24] Post-endoscopic retrograde cholangiopancreatography pancreatitis: a review
    Patel Parth S.
    Akshintala Venkata S.
    胰腺病学杂志(英文), 2024, 07 (01)
  • [25] Risk Factors and Risk Assessment for Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis
    Zhao, Chengjin
    Dai, Ting
    Qian, Junbo
    Ge, Zhenming
    JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN, 2024, 34 (04): : 413 - 418
  • [26] Post-endoscopic retrograde cholangiopancreatography pancreatitis assessed using criteria for acute pancreatitis
    Suzuki, Azumi
    Uno, Koji
    Nakase, Kojiro
    Mandai, Koichiro
    Endoh, Bunji
    Chikugo, Koki
    Kawakami, Takumi
    Suzuki, Takahiro
    Nakai, Yoshitaka
    Kusumoto, Kiyonori
    Itokawa, Yoshio
    Inatomi, Osamu
    Bamba, Shigeki
    Mizumoto, Yoshinori
    Tanaka, Kiyohito
    JGH OPEN, 2021, 5 (12): : 1391 - 1397
  • [27] Risk Factors for Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis in the Indomethacin Era - A Prospective Study
    Perdigoto, David N.
    Gomes, Dario
    Almeida, Nuno
    Mendes, Sofia
    Alves, Ana Rita
    Camacho, Ernestina
    Tome, Luis
    GE PORTUGUESE JOURNAL OF GASTROENTEROLOGY, 2019, 26 (03) : 176 - 183
  • [28] Nafamostat for Prophylaxis against Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis Compared with Gabexate
    Chang, Jae Hyuck
    Lee, In Seok
    Kim, Hyung Keun
    Cho, Yu Kyung
    Park, Jae Myung
    Kim, Sang Woo
    Choi, Myung-Gyu
    Chung, In-Sik
    GUT AND LIVER, 2009, 3 (03) : 205 - 210
  • [29] Effects of thalidomide in experimental models of post-endoscopic retrograde cholangiopancreatography pancreatitis
    Xiong, Guang-Su
    Wu, Shu-Ming
    Wang, Zhen-Hua
    Mo, Jian-Zhong
    Xiao, Shu-Dong
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2007, 22 (03) : 371 - 376
  • [30] Post-endoscopic retrograde cholangiopancreatography pancreatitis: A systematic review for prevention and treatment
    Pekgoz, Murat
    WORLD JOURNAL OF GASTROENTEROLOGY, 2019, 25 (29) : 4019 - 4042